The United States of America, As Represented by the Secretary, Department of Health and Human Services

Virginia Commonwealth University

University of Massachusetts

Organix, Inc.

George Kunos

Malliga R Iyer

Resat Cinar

Kenner C Rice

Raj K Razdan

Alexandros Makriyannis

Michael P Czech

Billy R Martin

William A Gahl

Myriam Aouadi

Bernadette R Gochuico

Karoly Varga

May Christine Vergara Malicdan

Aron Sanyal

Earl F Ellis

Tony Jourdan

Jens Wagner

Michael Paul Czech

A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CBreceptor mediating scaffold conjugated to (ii) a second therapeutic scaffold.

Cannabinoid receptor mediating compounds

A compound, or a pharmaceutically acceptable salt or ester thereof, comprising (i) a CBreceptor mediating scaffold and (ii) a second therapeutic scaffold.

Cannabinoid receptor mediating iminopyrazole compounds

A compound, or a pharmaceutically acceptable salt or ester thereof, having a structure of: wherein X and Y are each independently selected from optionally-substituted aryl, optionally-substituted heteroaryl, optionally-substituted cycloalkyl, optionally-substituted heterocycloalkyl, or optionally-substituted alkyl;

Pyrazole derivatives and their use as cannabinoid receptor mediators

Compositions comprising glucan-encapsulated siRNA directed against a region of the gene encoding the human CB1 receptor for use in the treatment of type 2 diabetes mellitus in a human subject. Additionally, methods for treating type 2 diabetes mellitus in a subject, comprising administering to the subject a composition comprising glucan-encapsulated siRNA directed against the CB1 receptor.

Glucan-encapsulated siRNA for treating type 2 diabetes mellitus

Fatty acid amide hydrolase (FAAH) is an enzyme responsible for the degradation of oleamide (an endogenous sleep-inducing lipid) and anandamide (an endogenous ligand for cannabinoid receptors). Disclosed herein are potent inhibitors of FAAH and methods for their use for treating a variety of disorder, including hypertension and cardiac hypertrophy.

Therapeutic applications of fatty acid amide hydrolase inhibitors

Methods and compounds for reversing pathological vasodilation of blood vessels, for example vasodilation caused by activation of CB1-like receptors, by administering to a subject a therapeutically effective amount of a compound sufficient to induce vasoconstriction, the compound comprising: wherein dashed lines independently represent either a single or a double bond, Ris a lower alkyl, Ris a lower alkyl, Ris a lower alkyl or halogen, Ris a lower alkyl or hydrogen, Ris a lower alkyl or hydrogen, Ris a hydrogen, lower alkyl or halogen, and Ris a hydrogen, lower alkyl or halogen. The vasoconstrictor can be used for a variety of purposes, including hemostasis or the treatment of shock, for example vasodilatory shock syndromes such as septic shock.

Vasoconstrictor cannabinoid analogs

Cannabinoids have been found to have antioxidant properties, unrelated to NMDA receptor antagonism. This new found property makes the cannabinoids useful in the treatment and prophylaxis of wide variety of oxidation associated diseases, such as ischemic, age-related, inflammatory and autoimmune diseases. The cannabinoids are found to have particular application as neuroprotuctants, for example in limiting neurological damage following ischemic insults, such as stroke and trauma, or in the treatment of neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease and HIV dementia. Nonpsychoactive cannabinoids, such as cannabidoil, are particularly advantageous to use because they avoid toxicity that is encountered with psychoactive cannabinoids at high doses useful in the method of the present invention. A particular disclosed class of cannabinoids useful as neuroprotective antioxidants is formula (I) wherein the R group is independently selected from the group consisting of H, CH , and COCH 

Vasodilator cannabinoid analogs

Hemorrhagic shock and in other conditions associated with excessive vasoconstriction, such as hypertension, peripheral vascular disease, cirrhosis of the liver, or certain forms of angina pectoris can be treated by using agonists of CB1 receptors as well as other cannabinoid receptors. In addition, it has been determined that in septic shock and cirrhosis of the liver when hypotension is due to activation of macrophages by bacterial endotoxin, the use of a drug that selectively blocks CB1 receptors or other cannabinoid receptors may be of therapeutic value by preventing or attenuating the endotoxin-induced hypotension.

Growing community of inventors

Bethesda, MD, United States of America

George Kunos